Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05475041
Other study ID # NP5467
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 30, 2022
Est. completion date July 22, 2022

Study information

Verified date July 2022
Source Fondazione Poliambulanza Istituto Ospedaliero
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The use of a simultaneous resection in patients with synchronous colorectal liver metastases has increased over the past decades. However, it remains unclear when a simultaneous resection is beneficial and when it should be avoided. The objective of this retrospective study is therefore to compare the outcomes of a simultaneous resection for synchronous colorectal liver metastases in different settings, and to assess which factors are independently associated with unfavorable outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 766
Est. completion date July 22, 2022
Est. primary completion date July 10, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Elective minimally invasive or open simultaneous resection of colorectal cancer and synchronous colorectal liver metastases Exclusion Criteria: - (Partially) robotic-assisted or thoracoscopic procedures - First stage of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) - Patients that underwent major concurrent procedures

Study Design


Intervention

Procedure:
Major liver resection
Major liver resection (3 or more contiguous segments)
Technically major liver resection
Minor liver resection (<3 contiguous segments) in the posterosuperior segments (segment 1,4a,7,8)

Locations

Country Name City State
Italy Fondazione Poliambulanza Istituto Ospedaliero Brescia Lombardy

Sponsors (17)

Lead Sponsor Collaborator
Fondazione Poliambulanza Istituto Ospedaliero Amsterdam UMC location University of Amsterdam, Antoine Béclère Hospital Paris, Clinica Universidad de Navarra Pamplona, Groeninge Hospital Kortrijk, Hospital Doctor Josep Trueta de Girona, IRCCS Azienda Ospedaliero-Universitaria di Bologna, IRCCS San Raffaele Hospital Milan, Moscow Clinical Research Centre, Oslo University Hospital and Institute of Medicine, Riuniti Hospital Polytechnic University of Marche Ancona, The Queen Elizabeth Hospital, Umberto I Mauriziano Hospital Turin, Università Cattolica del Sacro Cuore-IRCCS Rome, Universita di Verona, University Hospital Padua, University Hospital Southampton NHS Foundation Trust

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Major complications Severe complications (Clavien-Dindo grade 3a or higher) related to the surgical procedure 30 days postoperatively
Secondary Overall complications Overall complications related to the surgical procedure 30 days postoperatively
Secondary Length of hospital stay The length of hospital stay for the surgical procedure 30 days postoperatively
Secondary R0 resection margin Proportion of patients in whom a microscopically radical resection of both the primary colorectal carcinoma and the liver metastases was performed. 30 days postoperatively
Secondary Intraoperative blood loss Intraoperative blood loss in milliliters During the surgical procedure
Secondary Operative time Operative time in minutes During the surgical procedure
Secondary Conversion to open surgery Intra-operative conversion to an open or hand-assisted procedure in the minimally invasive group During the surgical procedure
Secondary Mortality Postoperative mortality 90 days postoperatively
Secondary Red blood cell transfusion Intraoperative red blood cell transfusion During the surgical procedure
Secondary Intraoperative incidents Intraoperative unfavourable incidents During the surgical procedure
See also
  Status Clinical Trial Phase
Recruiting NCT03941080 - Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Completed NCT03647839 - Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Terminated NCT02316496 - Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study Phase 2
Completed NCT03251612 - Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02380443 - AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer Phase 2
Recruiting NCT02149784 - Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients Phase 3
Recruiting NCT01959061 - Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Phase 4
Terminated NCT01668680 - Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma Phase 2
Recruiting NCT05068531 - Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
Not yet recruiting NCT04525807 - Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
Completed NCT04482608 - The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Recruiting NCT03193710 - The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved N/A
Recruiting NCT04854213 - PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) N/A
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03142516 - FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status Phase 2
Completed NCT03144804 - A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT01910610 - Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer Phase 3
Recruiting NCT05759728 - A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2